Tonix Pharmaceuticals Announces Positive Pre-IND Meeting with FDA for TNX-102 SL for the Treatment of Major Depressive Disorder

Tonix anticipates filing the IND application in the fourth quarter of 2025

TNX-102 SL is a potential first-in-class treatment for targeting the disturbed sleep associated with depression

Read more at globenewswire.com